![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Tuesday, April 11, 2023 9:08:32 PM
Send me $40K and I'll say ALMOST anything.
Diwan's name does not appear. Nor is their any mention of his relationship with the licensee.
And the Zach's Phd puts forth the same shaky proposition that NNVC's friend at Benzinga offered up:
"This is an important inflection point for NanoViricides as it is now transitioning to clinical-stage operations following a long development timeline as a pre-clinical company."
It is? NNVC is licensing 2 drugs to "someone else" to conduct the trials....the licensee will be conducting clinical-stage operations, not NNVC.
Some might say that that's just semantics. I prefer to call it misleading. And it's no small thing. Investors have been waiting for NNVC to run clinical trial for a long, long time....why aren't they actually doing it themselves, instead of just intimating that they are?
I didn't miss this.....
"Karveer has begun clinical development and evaluation of those two drugs and has obtained regulatory permissions to conduct clinical evaluation of them in India"
.....but it doesn't answer the question.
We've been we'll seeing for well over a decade.
No matter what it is or who commenced it, I'm against it!
....Groucho
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM